Regulatory Disclosure Summary

NATCO Pharma Limited has submitted a regulatory disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding a recent US FDA inspection.

Inspection Details

  • The U.S. Food and Drug Administration (USFDA) conducted an inspection of the Company's Formulation manufacturing facility located in Kothur, Hyderabad, India
  • Inspection period: November 12th to November 20th, 2026
  • Facility type: Formulations Manufacturing facility

Inspection Outcome

  • The Company received seven (7) observations in the Form-483 upon conclusion of the inspection
  • Company assessment: Believes the observations are procedural in nature
  • Company response: Confident of addressing these observations comprehensively within stipulated timelines

Facility Background

The disclosed facility is one of NATCO's manufacturing facilities that is approved by several leading regulatory authorities including US FDA, Brazil ANVISA, Health Canada, and WHO, catering to 50+ global markets.

Disclosure Purpose

This intimation is made in compliance with SEBI Listing Regulations requirements for disclosure of material events to stock exchanges.